Entrada Therapeutics Inc expected to post a loss of 79 cents a share - Earnings Preview

Entrada Therapeutics

05/05/2025 14:14

Entrada Therapeutics Inc TRDA.OQ TRDA.O is expected to show a fall in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

The Boston Massachusetts-based  company is expected to report a 82.8% decrease in revenue to $10.171 million from $59.12 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Entrada Therapeutics Inc is for a loss of 79 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Entrada Therapeutics Inc is $23.00​, above​ its last closing price of $9.23. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.67
-0.67
0.03
Beat
104.5
Sep. 30 2024
-0.71
-0.73
-0.35
Beat
51.9
Jun. 30 2024
0.14
0.15
1.55
Beat
969​
Mar. 31 2024
-0.61
-0.59
0.68
Beat
214.5
​​Dec. 31 2023
0.12
-0.17
-0.29
Missed
-72.6
Sep. 30 2023
-0.76
-0.74
1.02
Beat
238.6​
Jun. 30 2023
-0.68
-0.69
-0.78
Missed
-13
Mar. 31 2023
0.90
0.97
-0.21
Missed
-121.7

This summary was machine generated May 5 at 13:14 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)